TLR9 and prostate carcinoma: This model offers a therapeutic strategy to suppress the STAT3-mediated tumor survival effect in prostate cancer cells that is associated with TLR9 stimulation alongside boosting the antitumor immunity to skew the TLR9 activation response in favor of tumor killing.